Antimicrobial susceptibility testing in predicting the presence of carbapenemase genes in Enterobacteriaceae in South Africa by unknown
RESEARCH ARTICLE Open Access
Antimicrobial susceptibility testing in
predicting the presence of carbapenemase
genes in Enterobacteriaceae in South Africa
Ashika Singh-Moodley1* and Olga Perovic1,2
Abstract
Background: Carbapenem-resistant Enterobacteriaceae (CRE) is a concern in South Africa and worldwide. It is
therefore important that these organisms be accurately identified for infection prevention control purposes.
Method: In this study 1193 suspected CREs from 46 laboratories from seven provinces in South Africa were
assessed to confirm the prevalence of carbapenemase genes from our referral diagnostic isolates for the period
2012 to 2015. We compared the antimicrobial susceptibility testing method used in the reference laboratory to the
polymerase chain reaction (PCR) which is used as the gold standard. Organism identification and antimicrobial
susceptibility testing were performed using automated systems and DNA was extracted using a crude boiling
method. The presence of carbapenemase-producing genes (blaNDM, blaKPC, blaOXA-48&variants, blaGES, blaIMP and
blaVIM) was screened for using a multiplex real-time PCR.
Results: Sixty-eight percent (n = 812) of the isolates harboured a carbapenemase-producing gene; the three most
common genes included: blaNDM, blaOXA-48&variants and blaVIM. Majority of the carbapenemase producing
Enterobacteriaceae (CPE) isolates were Klebsiella species (71 %). The Microscan® Walkaway system used for the
screening of carbapenemase production was 98 % sensitive with a minimal inhibitory concentration (MIC)
breakpoint of less than 0.5 as susceptible for ertapenem and a low specificity (13 %).
Conclusion: From this study we can conclude that carbapenemase-producing Enterobacteriaceae is increasing in
South Africa and the use of phenotypic methods for detection of CPEs showed good sensitivity but lacked
specificity.
Keywords: Carbapenemase-producing Enterobacteriaceae, Antimicrobial susceptibility testing, Resistance genes,
Carbapenemases
Background
Multidrug resistant organisms are a major public health
concern [1, 2]. There is an increase in the global detec-
tion of antibiotic resistant Enterobacteriaceae strains
with antibiotic resistance observed to beta-lactams,
fluoroquinolones, aminoglycosides and polymixins [3].
Beta-lactam resistance mechanisms include outer mem-
brane permeability changes, efflux pumps and enzymes
that hydrolyse the antibiotic for example, the carbapene-
mases, including: the metallo-beta-lactamases (MBLs),
NDM, IMP and VIM; the oxacillinases, OXA-48 and
non-metallo-enzymes, Klebsiella pneumoniae carbapene-
mases (KPC) [3]. The emergence of resistance to the
broad-spectrum carbapenem group of antibiotics is par-
ticularly worrying as it limits treatment options and neces-
sitates the need for the use of antibiotics like tigecycline
and colistin which contribute to toxicity [4–6].
Carbapenemase-producing Enterobacteriaceae (CPE) are
carbapenem-resistant Enterobacteriaceae (CRE) that are
resistant to carbapenems due to carbapenemase produc-
tion [7]. Carbapenemases are beta-lactamases [8] that
hydrolyse almost all beta-lactams including the carbapen-
ems [3, 9]. Carbapenemases were initially chromosomally-
mediated in a few specific species, however majority are
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now plasmid-mediated, or both chromosomally- and
plasmid-mediated [10, 11] resulting in horizontal trans-
mission among various bacterial species and genera. The
ability of these mobile genetic elements (plasmids) to
acquire, harbour and disseminate multiple resistance
genes contributes to the successful and aggressive spread
of resistant organisms [12]. The presence of these genes
has been documented worldwide such as in Asia, Europe,
Australia and Africa including South Africa [13–32]. In
South Africa the first case of NDM in Enterobacter clo-
acae was reported in the Gauteng province in 2011 and
then almost a year later in KwaZulu-Natal. Klebsiella
pneumoniae isolates harbouring KPC, OXA-48 and OXA-
181were reported in Gauteng 2011. An outbreak of OXA-
181 in Klebsiella pneumoniae was documented in the
Western Cape in 2012 and the presence of OXA-48, VIM
and IMP in Enterobacter cloacae isolates isolated from pa-
tients in the Eastern Cape has also been reported [27–32].
The need to prevent the spread of these organisms is im-
portant, however, there are some obstacles. Many clinical
laboratories do not routinely test for CRE resistance-
mechanisms. They are therefore not able to differentiate
between non-susceptible CREs (which may be as a result
of carbapenemases or via combinations of ampicillin
class C (AmpC) enzymes, extended-spectrum beta-
lactamases (ESBL) and membrane impermeability), and
CPEs (which are as a result of carbapenemase produc-
tion exclusively) [33]. Furthermore, the Clinical and
Laboratory Standards Institute (CLSI) does not rec-
ommend molecular resistance-mechanism testing for
clinical purposes [34].
In this study, we evaluated1193 suspected CREs to
estimate the prevalence of CPEs in our sample popula-
tion in South Africa. This was not a surveillance study
but nonetheless provided us with baseline information
regarding the extent of CPEs in the country and the
organisms producing them. We also evaluated one of
the phenotypic methods routinely used for antimicrobial
susceptibility testing (AST) to determine its efficacy and
accuracy and report on its ability to screen for CREs
based on confirmed CPE genes received at the reference
laboratory.
Methods
The national Antimicrobial Resistance Laboratory
(AMRL) for the public healthcare sector, which majority
of the South African population have access to, have been
testing referred suspected CPE isolates for the presence of
selected carbapenemases. Clinically significant phenotyp-
ically identified carbapenem non-susceptible Enterobacte-
riaceae isolates were voluntarily submitted from 46
laboratories to the AMRL at the Centre for Opportunistic,
Tropical and Hospital Infections (COTHI), National
Institute for Communicable Diseases (NICD) for
confirmation of carbapenemase-producing genes as part
of a routine diagnostic programme. Isolates received for
the period 2012–2015 were analysed; it is important to
note that each isolate was analysed individually (for 179
patients, isolates from multiple sites and some repeats
were submitted). When the isolate was received at the
AMRL, organism identification was performed using au-
tomated systems (VITEK® II (bioMèrieux, France) and/or
the Microflex MALDI-ToF (Bruker Daltonik, GmbH) and
antimicrobial susceptibility testing (AST) was carried out
on the automated MicroScan® Walkaway system (Siemens,
USA) using the Gram-negative MIC Panel Type 44 (erta-
penem 0.5–1μg/mL; doripenem 1–4μg/mL; imipenem
1–8 μg/mL; meropenem 1–8 μg/mL). The Sensititre
instrument (Trek Diagnostic Systems, UK) was used
to clarify and confirm questionable Microscan results
(i.e. an isolate was phenotypically susceptible to the
carbapenems although a carbapenemase was present).
For this procedure, microtitre trays with two-fold
dilutions of antibiotics were inoculated with a stan-
dardised inoculum of the bacteria and incubated
under standardised conditions. The minimal inhibitory
concentration (MIC) was recorded the next day as
the lowest concentration of antimicrobial agent with
no visible growth. The interpretation of susceptibility
was done according to the Clinical and Laboratory
Standards Institute (CLSI) guidelines [34]. For geno-
typic testing, DNA was extracted using a crude boil-
ing method at 95°C for 25 minutes for cell lysis. The
supernatant was harvested and screened for blaNDM,
blaKPC, blaOXA-48 and its variants (OXA-162, 163, 244
245, 247, 181, 204, 232), blaGES (GES-1-9, 11), blaIMP
(IMP-9, 16, 18, 22, 25) and blaVIM (VIM-1-36) using
a multiplex real-time polymerase chain reaction
(PCR) (LightCycler 480 II, Roche Applied Science,
LightCycler 480 Probes Master kit and the individual
LightMix Modular kits (Roche Diagnostics, IN, USA).
Statistical analyses were performed using Graph Pad
Prism 5.
Results
In this study, in the period 2012–2015, we received 1193
suspected CREs to confirm CPE genes. We also evalu-
ated the phenotypic method used for antimicrobial
susceptibility testing and reporting of CREs.
From a total of 1193 isolates, 68 % (n = 812) har-
boured at least one or a combination of CPE genes. Of
these, 469 (57 %) were blaNDM-positive, 219 (26 %)
were blaOXA-48-positive (including variants), 89 (10 %)
were blaVIM-positive, 35 (4 %) were blaIMP-positive, 18
(2 %) were blaGES-positive and 11 (1 %) were blaKPC-
positive. Combinations consisted of blaNDM- and
blaOXA-48-positive (n = 8), blaNDM- and blaIMP-positive
(n = 4), blaNDM- and blaVIM-positive (n = 3), blaNDM-
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and blaKPC-positive, blaKPC- and blaVIM-positive, blaIMP-
and blaOXA-48-positive, blaVIM- and blaOXA-48-positive
(n = 2 each) and blaNDM- and blaGES-positive and
blaGES- and blaOXA-48-positive (n = 1 each).
Majority of the carbapenemase producing isolates were
Klebsiella spp. (71 %, n = 580) followed by Enterobacter
spp. (12 %, n = 101), Serratia marcescens (7.8 %, n = 63),
Escherichia coli (4 %, n = 35), Citrobacter spp. (3.9 %, n =
32), Providencia spp. (2.9 %, n = 24) and Morganella mor-
ganii and Raoultella spp. (0.4 %, n = 3, each). The predom-
inating genotype in most organism species was blaNDM
with the exception of Enterobacter spp. which also
included blaIMP. In E. coli the predominating genotype
was blaOXA-48 and its variants which were also commonly
found in all other organisms except in Providencia spp.,
Morganella morganii and Raoultella spp. (Fig. 1).
Specimen types in the carbapenemase producing
isolates were blood (32 %, n = 257), urine (21 %, n =
171), swabs (11 %, n = 87), body fluids (7 %, n = 59),
catheter tip (4 %, n = 35), sputum (3 %, n = 30) and
smaller percentages ranging from 0.1 % (n = 1) to 1.9
% (n = 16) for bone marrow, cerebrospinal fluid, stool,
upper respiratory tract, lower respiratory tract and
tissue specimens. Up to 26 % (n = 212) of the isolates
specimen types were unknown or the data were not
available (Fig. 2). There was no apparent correlation/
relationship between specimen type and organism or
specimen type and genotype.
BlaNDM predominated in the years 2012–2015 (71
%, n = 25; 49 %, n = 99; 50 %, n = 162 and 66 %, n =
183 respectively) followed by blaOXA-48 and its vari-
ants (11 %, n = 4; 19 %, n = 38; 32 %, n = 104 and 26
%, n = 73 respectively). In 2013, 16 % (n = 32) were
blaIMP-positive whereas in 2014 and 2015 there were
higher numbers of blaVIM-positive isolates (14 %, n =
47 and 8 %, n = 22 respectively) (Fig. 3). Statistical
analysis using the chi-squared test revealed that the
change in resistance mechanisms from 2012 to 2015
was significant (p < 0.0001) i.e. there was a significant
increase in the number of genotypes detected from
2012 compared to 2015.
Antimicrobial susceptibility testing profiles of these
carbapenemase producing isolates were analysed. Erta-
penem proved to be a reliable indicator of carbapene-
mase production. Ertapenem non-susceptibility was
observed in 98 % (n = 794) of the carbapenemase produ-
cing isolates indicating that the phenotypic method used
was fairly sensitive. Eighteen (2 %) isolates produced an
ertapenem-susceptible result although a CPE gene was
present (blaVIM, n = 10; blaNDM, n = 4; blaVIM, and
blaOXA-48-like, n = 1; blaIMP, n = 1; blaGES, n = 1 and
blaOXA-48 and variants, n = 1). Three of these isolates
were fully susceptible to the third and fourth generation
cephalosporins (cefotaxime, ceftazidime and cefepime)
as well as to the remaining carbapenems (imipenem, mer-
openem and doripenem). These isolates contained the
Fig. 1 Organism and genotype information in carbapenemase producing isolates
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following genes: blaNDM (n = 2) and blaOXA-48 and variants
(n = 1). Interestingly, 12 of these ertapenem-susceptible
isolates showed non-susceptibility to imipenem; two of
these were also non-susceptible to meropenem. Majority
(92 %, n = 11) of these were blaVIM-positive with one isolate
also positive for blaOXA-48 and its variants. The remaining
two isolates contained blaNDM (Table 1). Of the carba-
penem non-susceptible carbapenemase producing isolates,
one isolate was susceptible to cefotaxime, 12 were suscep-
tible to ceftazidime and 23 were susceptible to cefepime.
The carbapenemase types are seen in Table 2. The percent-
age susceptibility for the cephalosporins and carbapenems
is presented in Fig. 4. The susceptibility rates for cefotax-
ime, ceftazidime and cefepime decreased over the three
year period. There was a slight increase in the percentage
susceptibility for ertapenem over the three year period: 1 %
(n = 2) in 2013, 1.6 % (n = 5) in 2014 and 3.72 % (n = 10) in
2015), however overall the percentage susceptibility was
low.
Imipenem and meropenem were fairly good indicators
of carbapenemase production with non-susceptibility
observed in 77 % (n = 643) and 79 % (n = 661) of the car-
bapenemase producing isolates, respectively. A decrease
in the percentage susceptibility was also seen for imipe-
nem, meropenem and doripenem over time. It should be
noted that the instrument panel did not initially consist
of doripenem and it was therefore not tested for,
accounting for the low percentage obtained in 2013.
Fig. 2 Specimen type and genotype information in carbapenemase producing isolates. Citrobacter spp.: NDM, n = 27; KPC, n = 3; OXA-48, n = 1;
GES, n = 1. Enterobacter spp.: NDM, n = 31; KPC, n = 1; OXA-48, n = 29; IMP, n = 31; VIM, n = 9. E.coli: NDM, n = 11; OXA-48, n = 22, VIM, n =
2. Klebsiella spp.: NDM, n = 325; KPC, n = 7; OXA-48, n = 156; IMP, n = 2; VIM, n = 76; GES, n = 14. Morganella morganii: NDM, n = 3. Providencia spp.:
NDM, n = 21, IMP, n = 2; VIM, n = 1. Raoultella spp.: NDM, n = 2. Serratia marcescens: NDM, n = 49; OXA-48, n = 11; GES, n = 3
Fig. 3 Genotype information in carbapenemase producing isolates
over the 3 year period. 2012 – NDM n = 25, 71 %; KPC n = 2, 6 %;
OXA-48 n = 4, 11 %; IMP n = 2, 6 %; VIM n = 2, 6 %; GES n = 0. 2013 –
NDM n = 99, 49 %; KPC n = 6, 3 %; OXA-48 n = 38, 19 %; IMP n = 32,
16 %; VIM n = 18, 9 %; GES n = 9, 4 %. 2014 – NDM n = 162, 50 %;
KPC n = 3, 1 %; OXA-48 n = 104, 32 %;IMP n = 1, 0.3 %;VIM n = 47, 14
%;GES n = 9, 3 %. 2015 – NDM n = 183, 66 %; KPC n = 0; OXA-48 n =
73, 26 %; IMP n = 0; VIM n = 22, 8 %; GES n = 0
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Table 1 Minimal inhibitory concentrations (MIC) of ertapenem susceptible carbapenemase producing isolates
Sample
ID
ORGANISM NDM KPC OXA-48 &
variants














ML0148.2 Enterobacter cloacae - - - + - - >16 >32 >16 <=0.5 <=2 <=1 Not tested
ML0191 Klebsiella
pneumoniae
- - - - - + 8 >32 >16 <=0.5 <=2 <=1 Not tested
ML0440 Klebsiella
pneumoniae
- - - - + - 16 >32 >16 <=0.5 4 2 Not tested
ML0446 Klebsiella
pneumoniae
- - - - + - <=1 <=1 <=1 <=0.5 <=2 <=1 Not tested
ML0848 Klebsiella
pneumoniae
- - - - + - >16 >32 >16 <=0.5 4 <=1 <=1
ML0917 Providencia rettgeri + - - - - - <=1 <=1 <=1 <=0.5 <=1 <=1 <=1
ML0926 Escherichia coli + - - - - - <=1 <=1 <=1 <=0.5 <=1 <=1 <=1
ML0930 Klebsiella
pneumoniae
- - - - + - >16 >32 >16 <=0.5 4 <=1 <=1
ML1002 Providencia rettgeri + - - - - - 8 32 >16 <=0.5 >8 2 2
ML1007 Klebsiella
pneumoniae
- - - - + - >16 >32 >16 <=0.5 4 <=1 2
ML1161 Klebsiella
pneumoniae
- - + - - - >16 >32 >16 <=0.5 <=2 <=1 Not tested
ML1187 Escherichia coli - - + - + - 2 8 16 <=0.5 4 <=1 <=1
ML1189 Klebsiella
pneumoniae
- - - - + - >16 >32 >16 <=0.5 2 <=1 <=1
ML1219 Klebsiella
pneumoniae
- - - - + - 16 >32 >16 <=0.5 2 <=1 <=1
ML1279 Klebsiella
pneumoniae
- - - - + - >16 >32 >16 <=0.5 2 <=1 <=1
ML1296 Klebsiella
pneumoniae
- - - - + - >16 >32 >16 <=0.5 4 <=1 <=1
ML1340 Morganella morganii + - - - - - 8 >32 >16 <=0.5 8 <=1 2
ML1354 Klebsiella
pneumoniae
- - - - + - >16 >32 >16 <=0.5 4 <=1 2
CLSI breakpoints: Cefepime: <=2 – Susceptible, 4-8 – Susceptible-Dose Dependant, > = 16 – Resistant; Cefotaxime: <=1 - Susceptible, 2 – Intermediate, > = 4 – Resistant; Ceftazidime: <=4 - - Susceptible, 8 – Intermediate, > =















Table 2 Minimal Inhibitory Concentrations (MIC) of carbapenem non-susceptible, cephalosporin susceptible carbapenemase producing isolates
Sample
ID
Organism NDM KPC OXA-48&
variants














ML0056 Klebsiella oxytoca - - + - - - 16 8 <=1 >4 >8 >8 Not tested
ML0273 Klebsiella pneumoniae - - + - - - 2 4 <=1 >1 >8 >8 >4
ML0344 Providencia rettgeri + - - + - - 8 32 >16 4 >8 4 Not tested
ML0432 Serratia marcescens - - - - - + <=1 4 2 >4 >8 >8 Not tested
ML0484 Klebsiella pneumoniae - - + - - - <=1 2 <=1 >1 >8 4 4
ML0513 Klebsiella pneumoniae - - + - - - <=1 4 <=1 >1 4 8 4
ML0514 Klebsiella pneumoniae - - + - - - <=1 2 <=1 >1 2 4 4
ML0515 Klebsiella pneumoniae - - + - - - <=1 2 <=1 >1 4 >8 >4
ML0517 Klebsiella pneumoniae - - + + - - <=1 2 <=1 >1 4 4 4
ML0634 Serratia marcescens - - + - - - 8 >32 16 >1 >8 >8 >4
ML0794 Klebsiella pneumoniae - - + - - - <=1 <=1 <=1 >1 2 2 <=1
ML0825 Serratia marcescens - - + - - - 8 >32 16 >1 >8 >8 >4
ML0841 Serratia marcescens - - - - - + 8 32 8 >1 >8 >8 >4
ML0878 Providencia rettgeri + - - - - - 8 32 >16 >1 >8 >8 >4
ML0883 Serratia marcescens - - + - - - 8 >32 16 >1 8 >8 >4
ML0886 Serratia marcescens - - + - - - 8 >32 >16 >1 >8 >8 >4
ML0905 Serratia marcescens - - + - - - 8 4 2 >1 8 >8 >4
ML0910 Enterobacter
gergoviae
- - + - - - 4 4 <=1 >1 2 >8 >4
ML0918 Providencia rettgeri + - - - - - 8 32 >16 >1 >8 8 >4
ML0976 Escherichia coli - - + - - - <=1 2 <=1 >1 2 4 4
ML0999 Providencia rettgeri + - - - - - 8 32 >16 >1 >8 >8 >4
ML1167 Serratia marcescens - - + - - - 8 >32 16 >1 >8 >8 >4
ML1176 Providencia rettgeri + - - - - - 8 16 >16 1 >8 8 >4
ML1411 Klebsiella pneumoniae - - + - - - 8 >32 8 >1 8 2 4
CLSI breakpoints: Cefepime: <=2 – Susceptible, 4-8 – Susceptible-Dose Dependant, > = 16 – Resistant; Cefotaxime: <=1 - Susceptible, 2 – Intermediate, > = 4 – Resistant; Ceftazidime: <=4 - - Susceptible, 8 – Intermediate, > =















Of the 381 non-CPE isolates 333 (87 %) were pheno-
typically non-susceptible to ertapenem; 88 (23 %) were
non-susceptible to imipenem and 155 (41 %) were non-
susceptible to meropenem indicating that the phenotypic
method used lacks specificity particularly in the case of
ertapenem. Majority of the non-CPE isolates were Kleb-
siella spp. (49 %, n = 185) followed by Enterobacter spp.
(40 %, n = 154), Escherichia coli (6 %, n = 23), Morga-
nella morganii (2.7 %, n = 10), Serratia marcescens (1.5
%, n = 6), Proteus mirabilis. (0.5 %, n = 2) and Citrobacter
freundii. (0.3 %, n = 1). Specimen types varied: urine (27
%, n = 102), blood (20 %, n = 77), swabs (16 %, n = 60),
body fluids (7 %, n = 28), catheter tip (4 %, n = 16), spu-
tum (3.7 %, n = 14) and smaller percentages ranging
from 0.3 % (n = 1) to 1.6 % (n = 6) for cerebrospinal fluid,
upper respiratory tract, lower respiratory tract and tissue
specimens. Up to 18 % (n = 70) of the isolates specimen
types were unknown or the data were not available.
The overall antimicrobial susceptibility and PCR (gold
standard) results were compared to determine the sensi-
tivity, specificity, positive predictive value and negative
predictive value of the phenotypic method routinely
used (i.e. the MicroScan® Walkaway system). The sensi-
tivities, specificities, positive and negative predicted
values for ertapenem, imipenem and meropenem can be
seen in Table 3. The use of doripenem as a denominator
was omitted as it was not included in the AST panel for
all isolates tested.
Discussion
This study is a snapshot of the distribution of CPEs over
a period of three years and does not represent the
current burden of CPEs in South Africa. This study elu-
cidates the current prevalent circulating CPE types.
We observed that a high percentage (68 %) of the
isolates harboured at least one or a combination of
carbapenemase-producing genes. It should be noted
that although genotypic methods are remarkably reli-
able, there are some potential limitations. False-
negative results may be obtained as genes may not be
detected due to the presence of genetic variants and/
or rare carbapenemase types that were not included
in the screening e.g. SPM, SIM, IMI etc. This could
suggest that variants and other carbapenemases may
potentially have been missed suggesting that the actual
prevalence of CPEs in our study population could be
higher. This is worrisome as the rate of CPEs in South
Africa is increasing as indicated by the number of studies
reporting occurrences and outbreaks [27–32].
Majority of the CPE isolates (those harbouring carbape-
nemases) were Klebsiella spp. (71 %, n = 580) followed by
Enterobacter spp. (12 %, n = 101), Escherichia coli (4 %, n
= 35) and Citrobacter spp. (3.9 %, n = 32) were also
present to a smaller extent. Interestingly, we observed that
10.7 % (n = 90) of the carbapenemase producing isolates
belonged to one of the following organisms: Serratia mar-
cescens (7.8 %, n = 63), Providencia spp. (2.9 %, n = 24) and
Morganella morganii (0.4 %, n = 3). Carbapenem resist-
ance is particularly worrying in organisms such as these as
well as Proteus spp. as these organisms are intrinsically re-
sistant to colistin and if carbapenem cannot be used for
treatment, the management of patients infected with these
organisms is all the more challenging. Overall, in addition
to the carbapenems other antibiotics were analysed for all
carbapenemase producing isolates; with the exception of a
few (amikacin, tigecycline and colistin) which showed high
susceptibility, majority of the isolates showed varying de-
grees of resistance to the other antibiotics (ciprofloxacin,
gentamicin, trimethoprim/sulfamethoxazole, pipercillin/
tazobactam, ampicillin/sulbactam, aztroenam, cefotaxime,
Fig. 4 Percentage susceptibility to carbapenems and cephalosporins in carbapenemase producing isolates, 2013-2015. Data for 2012 was limited
and was excluded from this analysis
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ceftazidime, cefepime and cefpodoxime). Resistance to
these antibiotics may also be due to the presence of
AmpCs and/or ESBLs. Screening for these would provide
useful information for management purposes, however
this was not done.
The most predominant genotype in the carbapene-
mase producing Enterobacteriaceae group was blaNDM
(56 %, n = 469) followed by blaOXA-48 and its variants
(26 %, n = 219). BlaVIM, blaIMP, blaGES and blaKPC
were also present but on a smaller scale (11 %, n =
89; 4 %, n = 35; 2 %, n = 18 and 1 %, n = 11 respect-
ively). This is consistent with previous findings in
South Africa where these genotypes have been con-
firmed in both the public and private sector hospitals
in various provinces [27, 28, 30–32, 35]. There was a
marked increase in blaNDM and blaOXA-48 and its var-
iants from 2012 to 2015. This is a matter of concern
as it may indicate a possible emergence of these ge-
notypes which have the potential to become endemic.
The significant increase in the number of genotypes
detected from 2012 compared to 2015 further high-
lights this.
Phenotypically, ertapenem non-susceptibility is the
most sensitive indicator of carbapenemase production
[34]. This was observed in our study with ertapenem
non-susceptibility observed in 98 % of the carbapene-
mase producing isolates. Of these isolates approximately
3 % (n = 24) were non-susceptible to ertapenem but sus-
ceptible to the cephalosporins. According to the Clinical
and Laboratory Standards Institute, isolates displaying
non-susceptibility to ertapenem usually also test resist-
ant to one or more cephalosporin subclass III agents
(e.g. cefoperazone, cefotaxime, ceftazidime and ceftriax-
one), however some isolates producing carbapenemases
still continue to test susceptible to these cephalosporins
[34], a possible explanation for our outcomes. In sum-
mary, isolates displaying ertapenem-non-susceptibility
and cephalosporin-susceptibility may often be OXA-48
producers without harbouring an ESBL, which could
possibly be the case here. Three isolates were fully
susceptible to the third and fourth generation cephalo-
sporins as well as to imipenem, meropenem and doripe-
nem. This is interesting because except for CREs that
are OXA-48-like producers, most Enterobacteriaceae
that produce carbapenemases are generally resistant to
more than one antibiotic and resistant to third gener-
ation cephalosporins [33]. One of these isolates was an
OXA-48 producer but the other two have shown to pro-
duce NDM, suggesting that some organisms do not
conform to the traditional behaviour and patient man-
agement could perhaps be on an individual basis de-
pending on AST profiles and resistance mechanisms. It
should be noted that although the phenotypic result was
confirmed with two methodologies (Microscan and
Sensititre), the molecular result was only indicative of
the multiplex real-time PCR used and alternative
primers were not employed. Moreover, sequencing of
blaNDM was not performed which would further provide
subtype information. Non-traditional AST profiles were
also seen in other carbapenemase producing isolates
which were carbapenem non-susceptible but susceptible
to cefotaxime, ceftazidime or cefepime (Table 2). Major-
ity of these were OXA-48 producers. Furthermore, it
was observed that a small percentage (1.5 %, n = 12) of
ertapenem-susceptible isolates showed non-susceptibility
to imipenem with a further subset (0.3 %, n = 2) being
non-susceptible to meropenem as well. Majority of these
were VIM-producers suggesting that low MICs to ertape-
nem can be typical of certain VIM types, as VIM-producers
have variable kinetics for the different carbapenems. Hence
there is heterogeneity in expression within the same clone
and amongst different species [36, 37] and may in some
instances result in some VIM-types not being detected
phenotypically. Two percent of the carbapenemase produ-
cing isolates displayed fully carbapenem susceptible pro-
files. Previous studies have shown that the MIC
breakpoints for carbapenems in particular, imipenem and
meropenem were not elevated and in the susceptibility
range of <1 underscoring the difficulties in identifying
metallo-β-carbapenemase- producing organisms primarily
based on MIC results [16, 32].
While ertapenem has shown to be a reliable indica-
tor of resistance in the carbapenemase producing
Enterobacteriaceae group, phenotypic methods may
not be ideal as observed in the non-CPE group as
indicated by the high percentage (87 %) of non-CPE
ertapenem-non-susceptible isolates indicating that this
method lacks specificity. Imipenem and meropenem
showed better specificity (23 % and 41 %, respectively)
suggesting that all three antibiotics results should be
used to enhance specificity for CRE detection. It should
be noted however, that in instances where the
phenotypic method indicates resistance and the PCR
result is negative for all genes tested, resistance may
Table 3 Sensitivity, specificity, positive and negative predictive values of the microscan walkaway system
Antibiotic Sensitivity (%) Specificity (%) Positive predictive value (%) Negative predictive value (%)
Ertapenem 98 13 70 73
Imipenem 76 77 88 60
Meropenem 78 59 80 56
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be due to other carbapenemases, AmpC and or ESBL
gene/s not screened for by the PCR. Alternatively, other
mechanisms of resistance may be present e.g. efflux
pumps and porin mutations. The former statement may
be supported for example by the low cefoxitin suscepti-
bility rate (10.8 %) suggesting that plasmid-mediated
AmpC enzymes are very prevalent in our sample popu-
lation. Similarly, the low susceptibility rates for the pen-
icillins and cephalosprins (0.6–13 %) are indicative of
ESBLs. We have not screened for these. However, the
possibility remains that these isolates could in fact be
non-CPE. This is worrying as phenotypic methods are
routinely utilised and if ertapenem non-susceptibility is
strictly used as an indication to treat patients with car-
bapenems even though a carbapenemase is not present,
this would result in further implications towards poten-
tial antimicrobial resistance. This stresses the need for
specific tests that can routinely be used.
Overall the phenotypic method used for the detec-
tion of carbapenemase production was highly sensitive
for ertapenem (98 %) but the specificity was low (13
%), an indication that the method may possibly be
over-reporting results potentially influencing clinicians
to prescribe unnecessary antibiotics. For imipenem
and meropenem, the specificities were satisfactory but
the sensitivities were not. These antibiotics would
therefore not be the ideal antibiotic of choice for this
purpose.
Conclusion
We have shown an increase in carbapenemase-
producing Enterobacteriaceae over a three year period
with close to 40 % of all isolates received being blaNDM-
positive. Controlling the spread and limiting the impact
of CPEs in South Africa will require intensive efforts in
both the public and private healthcare sectors. The use
of phenotypic methods for detection of CPEs using erta-
penem is sensitive but lacks specificity and can be used
if there is no access to molecular methods. However,
conventional AST methods coupled with molecular
genotypic testing for the detection of carbapenemase-
producing Enterobacteriaceae is more definitive and
therefore advantageous.
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